Mifepristone

Generic Name: Mifepristone

Brand Names: Korlym, Mifegymiso

Drug Type: Small Molecule

Chemical Formula: C_₂₉H_₃₅NO_₂

CAS Number: 84371-65-3

Unique Ingredient Identifier: 320T6RNW1F

Background: Mifepristone is a progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercortisolism in patients with nonpituitary c...

Indication: For the medical termination of intrauterine pregnancy through 49 days' pregnancy. Also indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and are not candidates for surgery or have had unsuccessful surgery.

Associated Conditions: Hyperglycemia

Associated Therapies: Medically induced abortion

Clinical Trials

Mifepristone for Labor Induction

Phase 3

Completed

Conditions: Induced Vaginal Delivery

Interventions: Drug: Mifepristone
Drug: Misoprostol

First Posted Date: 2021-10-28

Last Posted Date: 2024-07-31

Lead Sponsor: Stanford University

Target Recruit Count: 30

Registration Number: NCT05097326

Locations: 🇺🇸
Lucile Packard Children's Hospital, Palo Alto, California, United States

Investigating the Potential Role of a Novel Quadrate Combination Therapy Mifepristone(Antiprogestrone), Tamoxifen, Retinoic Acid and Cannabidiol ( Selective Cyp 26 Inhibitor) for Treating Early Breast Cancer.

Phase 3

Conditions: Breast Cancer Female

Interventions: Drug: Mifepristone
Drug: 13-Cis Retinoic Acid plus Tocopherol
Drug: Standard therapy
Drug: All trans-retinoic acid
Drug: 9 cis retinoic acid
Drug: Cannabidiol
Drug: Tamoxifen

First Posted Date: 2021-08-23

Last Posted Date: 2021-08-23

Lead Sponsor: Mahmoud Ramadan mohamed Elkazzaz

Target Recruit Count: 160

Registration Number: NCT05016349

Assessing Use Of Mifepristone After Progestin Priming For Use As "Missed Period Pills"

Phase 2

Conditions: Missed Menstrual Period

Interventions: Drug: Levonorgestrel
Drug: Mifepristone

First Posted Date: 2020-12-21

Last Posted Date: 2021-08-12

Lead Sponsor: Gynuity Health Projects

Target Recruit Count: 139

Registration Number: NCT04676776

Locations: 🇲🇽
Cuidado Integral de la Mujer, Gineclinic, S.C, Mexico City, Mexico

Mifepristone Dynamic Testing for Diagnosis for Central Adrenal Insufficiency

Phase 2

Terminated

Conditions: Central Adrenal Insufficiency
Mifepristone

Interventions: Drug: Mifepristone

First Posted Date: 2020-10-19

Last Posted Date: 2023-06-12

Lead Sponsor: Tobias Else

Target Recruit Count: 3

Registration Number: NCT04588688

Locations: 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States

Improving Access to Abortion in the Republic of Georgia

Phase 4

Conditions: Pregnancy Related
Abortion Early

Interventions: Drug: Mifepristone

First Posted Date: 2020-07-07

Last Posted Date: 2020-07-07

Lead Sponsor: Center for Information and Counseling on Reproductive Health - Tanadgoma

Target Recruit Count: 120

Registration Number: NCT04458558

Locations: 🇬🇪
Batumi Medical Center, Batumi, Georgia
🇬🇪
Clinic Elite, Zestap'oni, Georgia
🇬🇪
David Gagua Clinic, Tbilisi, Georgia

TNF and Glucocorticoid Antagonist for GWI Associated Multi-symptom Disease Homeostasis Reset

Phase 1

Recruiting

Conditions: Gulf War Illness

Interventions: Drug: Etanercept
Drug: Mifepristone

First Posted Date: 2020-02-05

Last Posted Date: 2024-10-14

Lead Sponsor: Nova Southeastern University

Target Recruit Count: 20

Registration Number: NCT04254627

Locations: 🇺🇸
Miami VA Healthcare System, Miami, Florida, United States
🇺🇸
Nova Southeastern University, Davie, Florida, United States

Understanding GWI: Integrative Modeling

Phase 1

Conditions: Gulf War Illness
Persian Gulf Syndrome
Occupational Diseases

Interventions: Drug: Etanercept
Drug: Mifepristone

First Posted Date: 2020-02-05

Last Posted Date: 2020-02-05

Lead Sponsor: South Florida Veterans Affairs Foundation for Research and Education

Target Recruit Count: 20

Registration Number: NCT04255498

Locations: 🇺🇸
Miami VA Healthcare System, Miami, Florida, United States

Pilot Study of an Ambulatory Medical Abortion Service at 13-18 Weeks of Gestation in Colombia

Phase 4

Terminated

Conditions: Second Trimester Abortion

Interventions: Drug: Mifepristone
Drug: Misoprostol

First Posted Date: 2019-08-21

Last Posted Date: 2021-07-23

Lead Sponsor: Gynuity Health Projects

Target Recruit Count: 16

Registration Number: NCT04063904

Locations: 🇨🇴
Fundacion Orientame, Bogotá, Colombia

Assessing Medical Menstrual Regulation in the United States

Phase 2

Conditions: Menstrual Regulation

Interventions: Drug: Mifepristone
Drug: Misoprostol

First Posted Date: 2019-06-03

Last Posted Date: 2021-03-24

Lead Sponsor: Gynuity Health Projects

Target Recruit Count: 284

Registration Number: NCT03972358

Locations: 🇺🇸
Carafem Health Center, Chevy Chase, Maryland, United States

Mail Order Mifepristone Study

Phase 4

Completed

Conditions: Abortion Early
Pregnancy Related

Interventions: Drug: Mifepristone

First Posted Date: 2019-04-12

Last Posted Date: 2024-08-14

Lead Sponsor: Daniel Grossman, MD

Target Recruit Count: 536

Registration Number: NCT03913104

Locations: 🇺🇸
Delaware County Women's Center, Chester, Pennsylvania, United States
🇺🇸
Christiana Care Health System, Wilmington, Delaware, United States
🇺🇸
Highland Hospital, Oakland, California, United States

and more 8 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy